MATRIXLABS

Matrix Laboratories Limited has informed the Exchange that at the meeting of the Board of Directors of the Company, held on January 28, 2009 the Board has approved: (a) conversion of 1000 partly paid up equity shares of Rs.2/- each into fully paid up equity shares on account of receipt of calls in arrears. (b) forfeiture of 15500 partly paid up equity shares of Rs.2/- each, on account of non receipt of calls in arrears. The details of the forfeited shares shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common

Matrix Laboratories Limited has informed the Exchange that the Board of Directors of the Company at its meeting held on October 29, 2008, the Board approved: 1) Conversion of 6718 partly paid up equity shares of Rs.2/- each into fully paid up equity shares on account of receipt of calls-in-arrears. 2) Issue of a Final Notice to the Shareholders holding 16500 partly paid up Equity Shares of Rs.2/- each, advising them to remit the calls-in-arrears along with the interest on or before December 02, 2008.

Matrix Laboratories Limited has informed the Exchange on January 31, 2007, that: "The Board of Directors of the Company at their meeting held on even date considered and approved the following items : Agreement dated January 31, 2007 with Mr. Rajiv Malik pursuant to which Mr. Malik will continue as the Managing Director and acting Chief Executive Officer of the Company on deputation from Mylan Laboratories Inc. (USA), for whom Mr. Malik serves as Head of Global Technical Operations. An abstract of the terms and conditions of Mr. Rajiv Malik's agreement with Matrix would be forwarded to the Mem

(ii) Resignation of Directors (iii) Appointment of Additional Director (iv) Reconstitution of Committees. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Matrix_OBM_09012007.zip target=NEW> For more details click here.</a>

Matrix Laboratories Limited has informed the Exchange that: "The Board of Directors of the Company at their meeting held today i.e. 8th January, 2007 :- i) Noted that the transactions under the Share Purchase Agreement (SPA) between MP Laboratories (Mauritius) Ltd, a wholly owned subsidiary of Mylan Laboratories Inc. U.S.A. ('Acquirers'), and Mr. Prasad Nimmagadda, Prasad Nimmagadda-HUF, G2 Corporate Services Limited, India Newbridge Investments Limited, India Newbridge Partners FDI Limited, India Newbridge Coinvestment Limited, Maxwell (Mauritius) Pte Limited and Spandana Foundation ('the Sel

Matrix Laboratories Limited has informed the Exchange that the Board of Directors at their meeting held on January 30, 2006 considered, approved / recommended the following business :- 1) In principle approval for raising of funds upto a maximum of US $ 200 million by way of GDR / ADR / FCCB or shares on Preferential Basis or a combination thereof, subject to approval of the shareholders. This amount shall be utilized for the repayment of its bridge and/or term loan and also to meet its future growth requirements. 2) In principle approval for considering Employee Stock Option Plan (ESOP) to th

Matrix Laboratories Limited has informed the Exchange that the BODs of the Company vide circular resolution have approved the following business: (1) To issue 35,00,000 equity shares of Rs.2/- each on preferential basis, subject to the approval of the members, at a price of Rs.225 per share (including premium) amounting to Rs.787.50 millions to : (a) Mr. Pieter Van Rompay, 17,50,000 equity shares of Rs.2/- each and (b) Mr. Stijn Van Rompay, 17,50,000 equity shares of Rs.2/- each. (2) To convene an EGM of the company on December 19, 2005. Details of the press release titled, "Matrix plans pre

Matrix Laboratories Limited has informed the Exchange that the Board of Directors at their meeting held on July 28, 2005 considered and approved the following business: 1) Appointment of Mr. Rajiv Malik as an Additional Director and Chief Executive Officer of the Company. 2) Accepted the resignation submitted by Dr. C. Satyanarayana as Chief Operating Officer and confirmed his continuation as Non Executive Director on the Board of the Company. 3) Accepted the resignation submitted by Mr. N. Prasad as Chief Executive Officer and confirmed his continuation as Executive Chairman of the Company. 4

Matrix Laboratories Limited has informed the Exchange that the Board of Directors at their meeting held on April 26, 2005, considered and approved the following business: 1) Reconstitution of Audit Committee; 2) Allotment of 38,000 equity shares of Rs.2/- each annulling the forfeiture; 3) Approval for raising funds of approximately USD 200 Million by way of debt and / or equity related instruments / Global Depository Receipts / American Depository Receipts / Foreign Currency Convertible Bonds, subject to the approval of shareholders and other requisite approvals; 4) Acceptance of Resignation o

Matrix Laboratories Limited has informed the Exchange that the BOD's at their meeting held on January 22, 2005, considered and approved the following business: 1) Appointment of Mr. Arun Duggal as an additional director of the Company; 2) Allotment of 74841605 equity shares of Rs.2/- each on Bonus Issue; 3) Annulment of forfeiture of equity shares.

Matrix Laboratories Limited has informed the Exchange that the BOD at their meeting held on October 26, 2004 have considered and approved the following business, subject to the approval of the shareholders at the ensuing AGM : 1) Recommended final dividend of Rs.6/- per share for the financial year 2003 - 2004. 2) Sub-division (split) of equity shares of the company from the present face value of Rs.10/- each to Rs.2/- each per share. 3) Issue of Bonus shares in the ratio of 1:1.

Matrix Laboratories Limited has informed the Exchange that the Board has at its meeting held on October 26, 2004, considered and approved the following : 1) Taken on record the order received from the Hon'ble High Court of Andhra Pradesh dated October 13, 2004 approving the Scheme of Arrangement for Amalgamation of Vera Laboratories Limited, Fine Drugs and Chemicals Limited, Medikon Laboratories Limited and Calibre Engineering Private Limited into Matrix Laboratories Limited. The Appointed date for the merger is January 01, 2004. 2) Appointed Dr. Michael Wooldridge as an Additional Director of